Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15137456 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL3885456 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL8429329 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1668605 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL9232535 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1666654 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL5577129 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL3171119 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL9235193 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL11359586 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | claimed |
| EP-2314277-B1 | EXTERNAL PREPARATION FOR SKIN, AND WRINKLE-REPAIRING AGENT | KAO CORP (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-20110124586-A1 | EXTERNAL PREPARATION FOR SKIN, AND WRINKLE-REPAIRING AGENT | KAO CORPORATION (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2314277-A1 | EXTERNAL PREPARATION FOR SKIN, AND WRINKLE-REPAIRING AGENT | Kao Corporation (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-0653438-A2 | Oligonucleotide compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124586-A1 | EXTERNAL PREPARATION FOR SKIN, AND WRINKLE-REPAIRING AGENT | GLA, LGALS1, UGGT1 | LGALS3 80/4885LGALS1 2/4885LGALS9 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.